SCHEMBL20071967

SCHEMBL20071967

CC(C)(C)c1ccc2c(c1)N(c1ccc(-c3ccccc3)o1)C(C1N(c3ccc(-c4ccccc4)o3)c3ccc(C(C)(C)C)cc3N1c1ccc(-c3ccccc3)o1)N2c1ccc(-c2ccccc2)o1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PRKDC P78527 1/20 0.34
NQO2 P16083 2/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
KMT2A Q03164 1/20 0.33
NR1H3 Q13133 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
CYP2E1 P05181 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2A6 P11509 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2B6 P20813 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071966 0.81 MAOB (0.37) HPGDGFERSMN1; SMN2PRKDCNQO2
SCHEMBL20062958 0.81 PRKDC (0.34) HPGDGFERSMN1; SMN2PRKDCNQO2
SCHEMBL20071964 0.79 MAPT (0.31) HPGDSMN1; SMN2
SCHEMBL29273199 0.70 NQO2 (0.55) HPGDNQO2ERCC5FEN1CYP2E1
SCHEMBL20071774 0.70 AR (0.38) HPGDPRKDCNQO2NR1H3CYP2E1
SCHEMBL20681879 0.69 MEN1 (0.39) HPGDSMN1; SMN2KMT2ANR1H3
SCHEMBL23744356 0.69 NQO2 (0.54) HPGDNQO2ERCC5FEN1CYP2E1
SCHEMBL20071890 0.68 CHRNB2 (0.43) KMT2ACYP3A4
SCHEMBL25777967 0.67 L3MBTL1 (0.38) HPGDNR1H3CYP2D6DNMT1
SCHEMBL20071768 0.66 SCN10A (0.33) HPGDSMN1; SMN2KMT2ANR1H3SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 HPGD 3728/4885GFER 4057/4885SMN1; SMN2 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.